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ABSTRACT
Parasitic diseases of the central nervous system are associated with high mortality and morbidity,
especially in resource-limited settings. The burden of these diseases is amplified as survivors are often
left with neurologic sequelae affecting mobility, sensory organs, and cognitive functions, as well as
seizures/epilepsy. These diseases inflict suffering by causing lifelong disabilities, reducing economic
productivity, and causing social stigma. The complexity of parasitic life cycles and geographic specifi-
cities, as well as overlapping clinical manifestations in the host reflecting the diverse pathogenesis of
parasites, can present diagnostic challenges. We herein provide an overview of these parasitic diseases
and summarize clinical aspects, diagnosis, therapeutic strategies and recent milestones, and aspects
related to prevention and control.
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Introduction
Parasitic diseases affecting the central nervous system (CNS)
remain an important source of morbidity and mortality world-
wide. The neurological, cognitive, and mental health problems
caused by these parasitic infections affect millions of children
and adults in low- and middle-income countries; however,
sporadic cases also occur in nonendemic areas because of an
increase in international travel and immunosuppression
caused by post-transplantation therapy or HIV infection.
Long-term immunosuppression caused by medications such
as prednisone might also increase the risk for acquiring para-
sitic infections; however, information to support this hypoth-
esis is very scarce [1].
Parasites are a diverse group of organisms that can be
broadly classified into single-celled organisms (i.e. protozoa)
or multicellular helminths (i.e. metazoa) (Table 1). Protozoa
have the ability to multiply in the immunosuppressed, which
explains why most of the severe opportunistic infections in
patients with HIV are caused by protozoan parasites.
Helminths have the propensity to cause disease by physical
disruption of tissue as they migrate, provoking an intense,
often eosinophilic, inflammatory response [2]. Some hel-
minthic larvae can be very large, causing disease because of
their expanding mass. A relatively large number of parasites
infect humans, sometimes migrating through or lodging in
tissues, including the CNS [3]. Some parasites regularly cause
symptomatic disease, while others cause few, if any, symp-
toms. Concomitant infections are possible in areas endemic
for several parasites.
All parasites affecting humans might involve the CNS; how-
ever, the most common parasitic infection of the CNS is
cysticercosis. Other less frequent infections are toxoplasmosis,
echinococcosis and schistosomiasis. Rare parasitic diseases
involving the CNS are paragonimiasis, malaria, toxocariasis,
onchocerciasis, American trypanosomiasis [Chagas disease
(CD)], human African trypanosomiasis (HAT) and angiostron-
gyliasis [4]. These diseases have diverse causative organisms,
vector or intermediate hosts, modes of transmission and ende-
mic regions or geographic distributions (Table 2).
Clinical manifestations of the main parasitic diseases
of the CNS
Almost all parasitoses involving the human brain can be asso-
ciated with seizures and epilepsy, either by a diffuse encepha-
litis or encephalopathy, or by intracerebral location of the
parasite [5]. However, with the exception of neurocysticercosis
(NCC) and malaria, which are likely responsible for most of the
seizures attributed to parasitic disease worldwide, the fre-
quency of seizures because of parasites is not well documen-
ted in the literature [6,7]. In a recent study of people with
active epilepsy, exposure to multiple pathogens was common
[8]. The combined effect of Toxoplasma gondii and Onchocerca
volvulus co-infection on the prevalence of epilepsy seemed
more than additive. Some parasitic diseases cause eosinophilic
meningoencephalitis, which is characterized by specific clinical
manifestations and microscopic identification of eosinophils in
cerebrospinal fluid (CSF).
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Crossover between signs and symptoms, such as seizures,
eosinophilia (in blood or CSF) and fever, occurs with many
parasitic infections, thus making differential diagnosis a chal-
lenge (Figure 1). For example, a patient with parenchymal NCC
might only have seizures as a clinical manifestation; however,
another patient with extraparenchymal NCC might also have
eosinophilia and fever. Eosinophilia relates to the presence of
>500 eosinophils/ml of blood or an eosinophil count of >7%
of total leukocytes [9], while eosinophilia in CSF has been
arbitrarily defined by counts >10 eosinophils/ml or 10% of
the total CSF leukocyte count [2]. Helminthic infections are
the most common cause of eosinophilic meningoencephalitis;
nevertheless, other types of infections and neoplastic diseases
may be other causes.
Neurocysticercosis
The clinical manifestations of NCC are heterogeneous and
dependmainly on the localization of cysts and immune response
by the host. Seizures, headache, focal deficits and cognitive
abnormalities are the most frequent manifestations of cysts in
the brain parenchyma [10,11]. NCC predominantly affects adults
in their third and fourth decade of life, and is relatively
Table 1. Classification of parasitic infections of the central nervous system.
Protozoa Metazoa
Malaria Flatworms Trematoda Schistosomiasis
American trypanosomiasis Paragonimiasis
African trypanosomiasis Cestoda Cysticercosis
Toxoplasmosis Coenurosis
Amebiasis Hydatidosis
Microsporidiasis Sparganosis
Leishmaniasis Roundworms or Nematoda Gnathostomisasis
Angiostrongyliasis
Toxocariasis
Strongyloidiasis
Filariasis
Baylisascariasis
Dracunculiasis
Dicronemiasis
Lagochilascariasis
Table 2. Characteristics of main parasitic infections of the central nervous system.
Parasite disease Causative organism
Vector/intermediate
host Mode of transmission Endemic regions
Taeniasis/Cysticercosis Taenia solium Pigs, humans Fecal–oral, ingestion of eggs from human
feces (ingestion of larval cyst from pig
muscle leads to taeniasis)
Widespread throughout rural areas,
with poor sanitation, where humans
and pigs cohabitate: Latin America,
Africa, Asia
Toxoplasmosis Toxoplasma gondii Cats, intermediate
hosts in nature
(including birds
and rodents)
Ingestion of oocysts (cat feces) or tissue
cysts (undercooked meats), blood
transfusion, transplacentally from
mother to fetus
Worldwide, greatest burden in Sub-
Saharan Africa and Asia
Echinococcosis (Hydatidosis) Echinococcus
granulosus,
Echinococcus
multilocularis
EG: Sheep, goats,
cattle, pigs, yaks or
other farm animals
EM: Small mammals
(rodents
and lagomorphs)
Ingestion of
contaminated soil,
water or food,
contact with
infected animals
Middle East, Europe, Pacific, Latin
America; Inuit populations in North
America
Schistosomiasis Schistosoma
japonicum,
mansoni, and
haematobium
Fresh water snail Penetration of skin by cercariae in
freshwater
Tropical and subtropical areas of Sub-
Saharan Africa, Latin
America and Asia
Paragonimiasis Paragonimus
westermani
Freshwater snails,
crustacean-eating
mammals
Fecal–oral, raw, undercooked freshwater
crustaceans
East and Southeast Asia, West and
Central Africa, Central and South
America
Malaria Plasmodium
falciparum
Vector borne,
Anopheles
mosquito
Insect bite Tropics from Sub-Saharan Africa, Latin
America, Asia and Oceania
Toxocariasis Toxocara canis,
Toxocara cati
Cats, humans Fecal–oral, contaminated soil Worldwide
Onchocerciasis Onchocerca volvulus Blackfly (Similium) Insect bite West and Central Africa, as well as parts
of Central and South America
Chagas disease Trypanosoma cruzi Triatomine bug Insect bite Latin America
African trypanosomiasis Trypanosoma brucei
gambiense,
Trypanosoma
brucei rhodesiense
Tsetse fly Insect bite Africa
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uncommon in children and the elderly. Most pediatric patients
have a single transitional cyst that resolves spontaneously over a
few months [12]. Contrary to cysts in the brain parenchyma,
extraparenchymal cysts can be life threatening [13,14].
Extraparenchymal disease occurs in about one-third of
patients with NCC. Increased intracranial pressure also occurs
in patients with the racemose form of NCC and in those with
cysticercal encephalitis [13]. Acute hydrocephalus related to
intraventricular cysts, or chronic hydrocephalus because of
arachnoiditis or ependymitis are the most frequent causes of
this syndrome. Spinal cord cysticercosis is rare and patients
may experience nonspecific clinical manifestations, such as
nerve root pain or spinal cord compression syndromes,
according to the level of the lesion. Massive infection of
striated muscles can cause generalized weakness associated
with muscle pseudohypertrophy.
Toxoplasmosis
After ingestion of the organism, Toxoplasma gondii cysts may
develop in any tissue, but most commonly develop in the
brain, retina, skeletal muscle and cardiac muscle. Rupture of
the cysts releases the free tachyzoite, which causes acute
illness [4]. Fever, rash, lymphadenopathy and eye disturbances
are typical in early stages. When lesions are in the CNS of
immunocompromised patients, fever, headaches, confusion
and seizures are common, as well as ocular disease (retino-
choroiditis); however many infections are subclinical, and 20%
of HIV-infected patients with toxoplasmosis develop encepha-
litis. The disease may also be transmitted transplacentally and
have devastating effects on the fetal brain because maternal
antibodies passed to the child will be limited by the blood–
brain barrier. Seizures, microcephaly and chorioretinitis have
been noted in most of these cases.
Chronic infection in immunocompetent people, usually
considered asymptomatic, is suspected as a risk factor for
various neurological disorders, including epilepsy [5]. Few
well-conducted studies are available; only six studies were
identified in a systematic review [15], which estimated an
odds ratio of about 2. The odds of seizures are likely to be
dependent on the number and location of cysts. Some studies
have investigated whether Toxoplasma gondii infection may
also be a risk factor for development of depression and other
psychiatric disorders [16]. A recent experimental study used
Toxoplasma gondii to infect the brain of mice and showed that
seizures arise because of a defect in signaling of GABA, which
is the neurotransmitter primarily responsible for preventing
the onset of seizures [17].
Echinococcosis (hydatidosis)
The parasites Echinococcus granulosus and Echinococcus multi-
locularis causing cystic echinococcosis and alveolar echinococ-
cosis, respectively, belong to the same genus; however, these
pathologies are entirely different entities in terms of clinical
manifestations, course of disease and prognosis [18]. Alveolar
echinococcosis is currently considered a neglected ‘malignant’
parasitic disease and a threat to public health in Europe [19].
Recent reports have observed trends of Echinococcus multi-
locularis infection in the European fox and dog populations
and expect an increase of annual case numbers of human
alveolar echinococcosis in many areas of Europe within the
next decades [20,21].
The infection may be primary or secondary to the sponta-
neous or traumatic rupture of a primary cerebral cyst or
because of embolization of cardiac cysts [22]. Cysts may
remain asymptomatic until they are large enough to cause a
mass effect. Cerebral lesions occur in 1–4% of individuals with
cystic echinococcosis, with nonspecific clinical findings related
to those of space occupying lesions, increased intracranial
pressure and seizure activity.
Schistosomiasis
Schistosoma mansoni and Schistosoma haematobium are
almost always associated with spinal infection and
Schistosoma japonicum affects the brain. All three species
that infect humans have CNS complications, usually as a result
of the eggs causing infarction or granuloma formation. There
are substantial differences in the pathogenesis, clinical pre-
sentation and outcome of the neurological disorder, depend-
ing on the phase and clinical form [23].
Acute schistosomiasis, or Katayama syndrome, is an
immune-mediated hypersensitivity reaction to maturation
and migration of egg-laying schistosomes [9]. Fever, urticarial
rash, cough and pulmonary infiltrates are typical features, and
are often accompanied by a moderate peripheral eosinophilia.
Acute encephalitis, usually in the presence of a systemic illness
with fever and eosinophilia, occurs in about 2–3% of cases of
acute schistosomiasis [23]. Schistosomiasis is regarded as an
under-recognized cause of acute encephalopathy in the tro-
pics [24].
Patients with cerebral schistosomiasis are commonly
asymptomatic and may present with signs of space occupying
lesions, such as headache, seizures, papilledema, and visual
and oral disturbances [4]. Spinal schistosomiasis is often seen
in young male patients. Its localization in the lower cord and
conus region is explained by the free anastomosis between
Figure 1. Parasitic diseases of central nervous system according to presentation.
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the pelvic veins and the vertebral venous plexus [4]. The most
frequent form is myeloradiculopathy. There may be multiple
nodules in the spinal cord, cord compression from meningeal
granulomata and cord necrosis. Blood and CSF analysis usually
show eosinophilia and intrathecal specific antibodies. The CSF
findings are variable from normal, a mild pleocytosis, to mark-
edly raised protein. Identification of the Schistosoma is not
common and occurs in only about one-quarter of the patients
with myelopathy [22].
Paragonimiasis
The CNS is affected by the anomalous migration of larvae
through the bloodstream or through direct invasion of the
neural foramina of the skull base and intervertebral foramina
of the spine along the cranial and spinal vessels and nerves
[25]. Toxic substances produced by the parasite are responsi-
ble for aseptic inflammation or granulomatous reaction to the
parasite or its eggs. The initial intracranial lesions include
exudative aseptic inflammation, cerebral hemorrhage and
infarction. The wandering adult paragonimus makes tunnels
along the track of migration. The neurologic presentation is
nonspecific and can include headache, seizures and focal
neurologic deficits. Some patients can present intracranial
vascular injury because of the granulomatous inflammatory
reaction around tunnels along the migration track of the
parasite, resulting in cerebral hemorrhage [26].
Malaria
Malaria is the most common parasitic disease worldwide. It
affects primarily African children and Asian adults, with the
vast majority (>90%) of cases occurring in children 5 years old
or younger. Cerebral malaria is caused by Plasmodium falci-
parum and may result in an acute encephalopathy (with feb-
rile and acute seizures), which may be fatal or lead to
polymorphic neurological sequelae.
The pathophysiology of brain involvement is multifactorial
but is related to the degree of parasitemia, sequestration of
schizonts in the brain venules, and the resulting vascular and
perivascular damage [22]. Suggested mechanisms of injury
include anoxia, vascular leakage, parasite toxin, metabolic
derangements, increased intracranial hypertension, including
stroke and others [5]. The first symptoms of malaria are non-
specific, and include headache, fatigue, abdominal discomfort,
muscle aches and irregular fever. Nausea, vomiting and ortho-
static hypotension also occur frequently. Generalized seizures
might be followed by coma [27]. For those who survive cere-
bral malaria, residual neurological abnormalities are common.
Epilepsy, cognitive impairment, behavioral disorders and gross
neurological deficits are frequent sequelae. There is a clear
association with epilepsy, which has been reported by some
epidemiological studies in endemic areas in Africa [7].
Toxocariasis
There are three main syndromes associated with toxocariasis:
visceral larva migrans, which encompasses diseases associated
with major organs; covert toxocariasis, which is a milder
version; and ocular larva migrans, in which the pathological
effects on the host are restricted to the eye and the optic
nerve. CNS infestation is rare, but these patients may present
with seizures, eosinophilic meningitis, optic neuritis and
meningomyelitis. A systematic review evaluating the strength
of the association between epilepsy and Toxocara spp. sug-
gested that seropositivity for Toxocara spp. is significantly
higher among people with epilepsy [28]. However, the inclu-
sion of prevalent rather than incident cases does not allow
distinguishing among the potential etiological factors that
preceded the onset of epilepsy and thus, cause and effect
become difficult, if not impossible, to establish.
Onchocerciasis
In onchocerciasis or river blindness, symptoms include severe
itching, bumps under the skin and blindness. It has also been
proposed to be a potential risk factor for epilepsy because of the
high prevalence of onchocerciasis in areas with a high preva-
lence of epilepsy. Analytical work on this association has pro-
duced conflicting results, perhaps related to confounders (e.g.
other CNS infections) or a lack of standardized methods [5]. A
recent meta-analysis showed a significant association with an
odds ratio of around 3 [29]. Onchocerciasis has been suggested
to cause nodding syndrome, an epileptic encephalopathy char-
acterized by nodding of the head, affecting mainly children in
Africa [30]. Some studies suggest an association with onchocer-
ciasis, but this requires further investigation [31].
American trypanosomiasis (Chagas disease)
CD is endemic to Latin America, but is increasingly found in
other parts of the world, including countries previously free of
disease [32]. CNS involvement in CD may occur in a small
percentage of patients in the acute phase. Reactivation of latent
infection in chronic CD has been reported in immunosup-
pressed patients [4]. Chagas meningoencephalitis may manifest
as the first presentation of AIDS. The definitive diagnosis
depends on characterizing the parasite in CSF tests or by histo-
logic analysis of the cerebral parenchyma. CD is probably an
under-recognized cause of ischemic stroke in South America, as
some epidemiological studies have found an association
between Trypanosoma cruzi infection and ischemic stroke [33].
Human African trypanosomiasis (sleeping sickness)
HAT infects the brain parenchyma by early seeding in the
choroid plexus and secondary passage into the CSF, or by
direct passage into the cerebral capillaries. Once these vessels
are involved, the extracellular spaces within the white matter
allow the parasite to move into the brain tissue [9]. The early
stage (stage 1, early hemolymphatic stage) corresponds to the
development of the parasite in blood and lymphatic tissue.
Later (stage 2, late encephalitic stage) in the absence of treat-
ment, the CNS becomes involved [3]. The symptoms of HAT
range from meningitis to meningoencephalitis with brain
edema and arachnoiditis. Seizures may appear in the terminal
phase of the disease and death occurs without treatment.
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Angiostrongyliasis
Angiostrongylus cantonensis occurs widely in the tropics. Most
infections occur in Southeast Asia, but small epidemics have
been reported more recently from the Caribbean and elsewhere.
Angiostrongylus cantonensis is a zoonotic parasite that affects rats
as the primary hosts. Humans are infected by eating larvae in
undercooked intermediate hosts (e.g. snails, slugs, crabs, or
prawns). Angiostrongylus cantonensis is the most important etio-
logical agent of eosinophilic meningitis. The larvae migrate to the
CNS, where they can be identified in the meninges, blood vessels
and perivascular spaces. Angiostrongyliasis is an acute disease
that spontaneously resolves and rarely entails sequelae or fatality.
It most often presents with headaches, nausea, vomiting and
neck stiffness. Fever is uncommon, but other features of menin-
gitis, encephalitis and radiculitis may occur. Lumbar puncture
pressure is usually raised, with turbid CSF. The pleocytosis usually
has eosinophils and occasionally the larvae are seen. There is no
specific treatment and most illness resolves in 4–6 weeks.
Immunological and molecular diagnosis of the main
parasitic infections of central nervous system
Parasitic infections of the CNS are often ‘silent’, with the
classical neurological symptoms (e.g. headache, seizures,
coma) appearing long after the initial invasion of the brain
and, importantly, when considerable, sometimes irreversible,
damage has occurred. Thus, early and reliable confirmatory
diagnosis subsequent to clinical examination is an essential
tool in the control and treatment of these debilitating infec-
tions, with detection of viable parasite as a key objective,
rationally opening the door to appropriate and effective treat-
ment. Direct visualization of the parasite, as for cerebral
malaria, HAT and toxoplasmosis, is clearly definitive. In many
parasite infections, however, this is not a feasible option, and
so the development of specific and sensitive serodiagnostic
and molecular biological [polymerase chain reaction (PCR)]
assays for viable parasites is an urgent priority that will com-
plement and confirm clinical examination.
In the hospital situation, where the neurologist routinely
takes CSF samples from patients exhibiting neurological symp-
toms, detection of secretions from viable parasites or detec-
tion of parasite DNA in CSF would be the preferred option,
although the location of the parasite in the brain may be an
important factor. For example, in the diagnosis of NCC,
through detection of the secreted metacestode glycoprotein
using the HP10 antigen assay, the location of the cyst is an
important factor functioning well for extraparenchymal NCC,
but not so sensitive for parenchymal NCC [14]. On the other
hand, for investigation in a rural endemic setting, serum is
clearly the only practical possibility for HP10 assay, and one
must accept the fact that while there may be false positives
and false negatives, an endemic focus has been identified for
further studies and for referral to appropriated hospital
facilities.
The detection of parasite DNA through the PCR is an
experimentally simple approach and is currently receiving
much more attention than serological detection of secreted
products of viable parasites. Unfortunately, parasite DNA can
originate from both the live and dead organism and thus, a
positive PCR is not necessarily definitive proof of a viable
parasite infection. The strength of the PCR, however, is its
sensitivity and exquisite specificity, which are characteristics
that provide a powerful tool for the differential diagnosis of
parasite subtypes and polymorphisms and for molecular epi-
demiological investigations.
Anti-parasite antibodies are synthesized soon after host
invasion and so their detection is still the most frequently
employed diagnostic tool. Once again, however, their detec-
tion is not definitive proof of a current, viable infection as
antibodies can persist for months, even years, after elimination
of the parasite, for example by drug treatment.
For antibody diagnosis of cerebral parasitic infections, both
serum and CSF samples are commonly employed. The pre-
sence of antibodies in CSF is a clear indication of cerebral
involvement and damage, but does not necessarily exclude
the presence of the parasite in other body locations. Similarly,
the presence of serum antibodies may, or may not, indicate a
cerebral infection with consequent impact on the blood–brain
barrier. Importantly, the demonstration of anti-parasite anti-
bodies, being clear evidence of exposure to the parasite, is an
extremely useful tool for the evaluation of parasite endemicity
at the level of a population before, during and after control
programs.
Finally, in spite of their recognized lack of specificity, solu-
ble parasite extracts are still commonly used as ‘antigens’ in
anti-parasite antibody assays. Today, with the ready availability
and reproducibility of recombinant and monoclonal antibody
technology, this practice should cease. With these preliminary
considerations in mind, current diagnostic procedures for the
detection of main parasitic infections of CNS are herein
summarized.
There has been considerable investigation into the devel-
opment of serological and molecular biological procedures for
the diagnosis of NCC [34]. Not surprisingly, therefore, a variety
of recombinant metacestode antigens and synthetic peptides
have been tested as target for antibody detection. Amongst
these, particularly useful examples are the cathepsin L-like
protease and the T24H and Ts8B2 recombinant proteins
[35,36]. Simple, sensitive, specific and economic enzyme-
linked immunosorbent assay (ELISA) assays detecting antibo-
dies to reproducible, recombinant antigens are clearly a pre-
ferred alternative to the enzyme-linked immunotransfer blot
(EITB), which is expensive, technically more complicated and
requires parasite material.
As an alternative to the antibody assays, the detection of
molecules secreted by viable metacestodes has been met
with success [37,38], and their utility in the diagnosis and
treatment of NCC has been demonstrated [14,39–41]. A par-
ticularly useful application of the viable metacestode
secreted antigen detection assay is the long-term follow up
of patients with NCC before, during and after drug treatment.
Thus, effective drug treatment of patients with NCC is clearly
established by the decreased antigens levels in CSF, whereas
ineffective treatment is revealed by the continued presence
of the secreted parasite product in the CSF. Finally, some
success in the diagnosis of NCC in CSF has been realized
through PCR [42].
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Like malaria, the ‘gold standard’ for diagnosis of toxoplas-
mosis is detection of the parasite by microscopy.
Complementary techniques include detection of circulating
Toxoplasma gondii antigens, anti-toxoplasma antibodies, and
a variety of PCR protocols [43]. Diagnosis at the level of clonal
types is now possible through DNA sequencing and the ser-
ological identification of antibodies to polymorphic toxo-
plasma peptide sequences, and these are useful tools for
both clinical and epidemiological studies. Confirmation of
neonatal toxoplasmosis is highly important and definitive by
the detection of IgM antibody in CSF, typically using either the
indirect fluorescein antibody test or the Sabin–Feldman dye
test. Diagnosis of toxoplasmosis in immunocompromised
patients is complicated by immunosuppression and frequently
low antibody titers. A serious practical problem is to distin-
guish infection with Toxoplasma gondii from cerebral infection
with Trypanosoma cruzi; in these patients, diagnosis demands
a combination of serology, PCR and examination of CSF.
Diagnosis of cerebral echinococcosis follows the common
pattern of serological confirmation subsequent to the obser-
vation of neurological symptoms. Diagnostic testing for anti-
parasite antibodies using parasite extracts or a western blot-
ting protocol has been described [34].
Invasion of the brain has been described for all of the
Schistosoma species infecting humans, and the full importance
of this clinical entity and its consequence for the proposed
massive population dosing of the drug praziquantel is yet to be
fully appreciated. Diagnosis following suspicious clinical symp-
toms is usually through the demonstration of Schistosoma eggs
in feces or urine and through the detection of antibodies to the
soluble egg antigen [2]. There is a need for more work here.
Paragonimiasis is confirmed by detection of the parasite
and the demonstration of anti-parasite antibodies following
the observation of neurological symptoms. The preferred ser-
ological diagnostic test uses a western blotting procedure to
detect antibodies to an 8 kD protein of the adult [44].
Like toxoplasmosis, the standard for diagnosis of cerebral
falciparum malaria is direct visualization of the parasite in
blood smears. There are PCR protocols and immunodiagnostic
tests detecting antibodies to parasite proteins, such as the
histidine-rich protein and lactate dehydrogenase [45]. Apart
from their expense, the latter tests are criticized for not pro-
viding a reliable estimate of parasite load.
Although rare, cerebral toxocariasis does occur and, follow-
ing neurological symptoms, the preferred confirmation is
through detection of antibodies to eggs antigens or secretions
of infective larvae, preferably in CSF [46].
Cerebral complications associated with HAT are usually first
detected through antibody-mediated agglutination of fixed try-
panosomes, a technique known as the ‘Card Agglutination Test
for Trypanosomes’ (CATT), and then confirming the diagnosis by
direct visualization of the parasite in CSF. Both false positive and
false negative have been reported using the CATT [34].
As for toxoplasmosis, the main challenges for CD are: the
low antibody titer in young children and immunosuppressed
individuals, and the difficulty of distinguishing Trypanosoma
cruzi from Toxoplasma gondii. Once again, a combination of
serology, PCR and examination of CSF for parasite is required.
In addition to various antibody detection tests, a technique to
detect antigens present in a crude excretion/secretion product
has been described [47].
Neuroimaging diagnosis of parasitic infections of the
CNS
Neuroimaging studies (CT scan and MRI) play an important
role in early diagnosis; however, there is a wide range of
neuroimaging findings in parasitic infections of the CNS,
often with considerable overlap, which makes determination
of a specific diagnosis difficult. Therefore, correlation with
laboratory tests, especially CSF analysis, is considered to be
fundamental in establishing a definitive diagnosis. In addition
to conventional CT and MRI, advanced neuroimaging techni-
ques, such as fluid attenuation inversion recovery (FLAIR),
diffusion MR, perfusion MR, and MR spectroscopy have been
employed, as well as the 3D MRI sequences [Fast Imaging
Employing Steady-state Acquisition (FIESTA) and Spoiled
Gradient Recalled Echo (SPGR)] which provide more clues for
differentiation of CNS parasitic diseases, especially for
NCC [11].
Parasitic disease in the CNS develops inflammation
revealed by hypercellularity and as a consequence of
edema. The cellular malfunctions develop breakdown of
the blood–brain barrier, which is evident by imaging studies.
These abnormalities are overlapping for several other inflam-
matory, infectious, and space-occupying lesions, such as
metastatic disease, gliomas, demyelinating disease, resolving
cerebral hemorrhages, subacute infarctions, tuberculomas,
and cerebral abscesses [48]. Infectious and noninfectious
inflammatory lesions characteristically show low-density
change (CT) or high signal change (T2 MR imaging) consis-
tent with edema and associated swelling, mass effect, and
shift may be present. Therefore, acuity on neuroimaging is
variable; it may wax and wane. It may be a one-time man-
ifestation; it may vary with treatment; or may be chronic
[49]. At times, imaging shows more specific disease features
that may allow a more precise diagnosis, as in cases of NCC
and echinococcosis.
Neuroimaging is useful in diagnosis of NCC, as it permits
visualization of the parasite evolutionary stage, as well as
number and localization of lesions [11]. Specifically, imaging
procedures allow visualization of vesicular, colloidal, granular-
nodular and calcified phases of the parasite in the CNS
(Figure 2). MRI is more sensitive than CT for the detection of
the scolex and for the diagnosis of extraparenchymal
NCC [4,49].
In the vesicular phase, the CT scan depicts circumscribed,
round, hypodense areas, varying in size and number, without
enhancement by contrast media. In the MRI, the vesicular larva
appears with a CSF-like intensity signal on all sequences, with no
surrounding high signal on T2-weighted images. Both MRI and
CT may show a high intensity or hyperdense, 2–3 mm mural
nodule depicting the scolex, within some vesicular cysts. As the
cyst degenerates, the contrast-enhanced CT scan shows an annu-
lar (colloidal phase) or nodular (nodular phase) enhancement
surrounded by irregular perilesional edema. In this phase, the
fluid content gives a slightly higher signal than CSF and is
occasionally isodense with the parenchyma on MRI-T1 and/or
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proton density-weighted, and high signal on T2 images. The
capsule shows a higher signal than the adjacent brain, with
thick ring enhancement on T1 images, while on T2 images
there is a low ring signal surrounded by high signal lesion, due
mostly to edema. When the cyst dies it may disappear or
become an inactive calcified nodule with homogeneous high
density on CT or low intensity on proton-weighted MRI.
Extraparenchymal NCC is more difficult to detect by ima-
ging because the attenuation and signal intensity of the cyst’s
content is similar to that of CSF, the cystic wall is usually not
detected, there is not enhancement after intravenous contrast
administration, and the cysts frequently lack a scolex. MRI
techniques such as FLAIR and FIESTA sequences permit better
detection of the parasites (Figure 2). In case of meningeal
inflammatory process, gadolinium enhancement of MRI or
contrast-enhanced CT may depict leptomeningeal thickening.
Occasionally, a grape-like cluster of cysts (racemose form)
without scolices may arise in the cisterns and sylvian fissure
and does not show associated enhancement or progression
through the stages described above [50].
Neuroimaging studies in patients with toxoplasmosis com-
monly show multifocal abscesses with a predilection for the
basal ganglia. However, solitary lesions have been noted in
about one-third of patients. Most lesions show enhancement,
often in a ring-like pattern. The eccentric target sign, which is
characterized by a small nodule, along the wall of the enhan-
cing ring, has been reported to be highly suggestive of a
diagnosis of toxoplasmosis [51].
The imaging appearance of toxoplasmosis may overlap that
of CNS lymphoma and other neoplasms. Subcortical location,
eccentric target sign, absence of corpus callosal or leptome-
ningeal involvement, and marked edema are imaging findings
that favor toxoplasmosis, whereas hyperattenuation, hypoin-
tensity on T2-weighted images, restricted diffusion, and peri-
ventricular location favor CNS lymphoma. MR spectroscopy
can be helpful in the differential diagnosis [52].
Hydatid cysts in imaging studies appear as large, well-
defined, smooth, thin-walled, cystic lesions that are spherical
or oval in shape, usually with no surrounding edema. The cyst
contents typically have CSF-like density on CT and CSF-like
signal characteristics on all MR sequences. On post contrast
images, a thin rim of enhancement may be seen. The presence
of a daughter cyst within a cystic lesion is considered pathog-
nomonic of an echinococcus cyst [53].
Neuroimaging findings in schistosomiasis are variable and
nonspecific. On CT, single or multiple variably enhancing
hyperattenuated lesions with surrounding hypoattenuated
edema may be present and reflect a focal granulomatous
reaction [22]. MRI shows foci of low signal on T1 and high
signal on T2, with contrast enhancement. A characteristic MR
imaging pattern of lesions is a large mass comprising multiple
intensely enhancing nodules, sometimes with areas of linear
enhancement. Central linear enhancement surrounds multiple
enhancing punctate nodules, forming an ‘arborized’ appear-
ance [54]. Although this pattern is highly suggestive, it is a rare
presentation.
Figure 2. Imaging findings in patients with neurocysticercosis. A) MRI of parenchymal vesicular cyst with scolex. B) MRI of colloidal cysticerci with perilesional
edema. C) CT scan of many calcified parasites. D) MRI of intraventricular cysts.
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On MRI, conglomerates of multiple ring shaped shadows
or enhancement of so-called ‘soap bubble’ forms in one
hemisphere is a suggestive image of paragonimiasis. On
CT, multiple calcifications with round or oval shapes sur-
rounded by low-density areas, cortical atrophy and ventri-
cular dilation are seen [4]. Chagas meningoencephalitis
usually manifests as multiple expanding hyperintense
lesions on T2-weighted images with nodular or annular
enhancement in imaging studies. Additionally, it may be
seen in the spinal cord. These findings are quite similar to
those displayed in toxoplasmosis and CNS lymphoma. On
MRI, HAT shows meningeal thickening, with multiple white-
matter T2 hyperintense lesions or meningeal enhancement
and diffuse hypoattenuated areas affecting the white matter
in both hemispheres on CT. MRI toxocariasis images show
unspecific circumscribed, multifocal lesions in the brain
white matter, with contrast enhancement. Imaging findings
in cerebral malaria include cerebral edema, cortical and
subcortical ischemic lesions, and multiple petechial hemor-
rhages [53].
On MRI, angiostrongyliasis often reveals multiple micronod-
ular enhancements in brain tissues and linear enhancement in
the pia mater. Complete resolution of abnormal MRI findings
typically occurs after 4–8 weeks. Micronodules have also been
detected in MR imaging of lungs, which may reflect the pre-
sence of worms [2].
Overview of medical treatment of parasitic infections
of the CNS
Analogous to their heterogeneity in clinical presentation,
treatment of parasitic infections of the CNS is diverse and
spans both medical and surgical treatment. Medical treatment
often involves pharmacotherapy to kill the parasite and
adjunctive care to prevent or treat complications related to
infiltration of the parasite (e.g. anticonvulsants for patients
presenting with seizures). Similarly, surgical treatment might
involve physical removal of the parasite (e.g. cysts in the CNS)
or treating complications of the parasite (e.g. hydrocephalus).
Antiparasitic drugs are indicated for most parasitic infec-
tions of the CNS (Table 3) [22,55]. However, there are some
exceptions when the risks of treatment outweigh its potential
benefits, particularly when antiparasitic treatment may result
in host inflammatory responses that are uncontrollable, dan-
gerous, or destructive. In other instances, antiparasitic treat-
ment may simply be ineffective because the parasite is already
dead, but still causing symptoms (e.g. calcified NCC).
Antiparasitic treatment may also be adjunctive to surgery,
such as in echinococcosis, where perioperative antihelminthic
drugs can facilitate cyst removal and prevent cyst
regeneration.
The efficacy of antiparasitic drugs varies widely. In cerebral
malaria, for example, the drugs are effective, but mortality
remains high, so much research has focused on optimizing
adjunctive care to reduce mortality. In other infections, anti-
parasitic drugs may have suboptimal efficacy or be highly
toxic, demonstrating an unmet need for new antiparasitic
drugs, some of which are in the clinical pipeline, such as
fexinidazole for CD and HAT. Despite these challenges, high
quality research has been able to establish a more reliable
evidence base for treating and managing some of these
‘neglected’ infections.
Recent progress in the treatment and management
of parasitic infections of the CNS
For NCC, substantial progress has been made in treatment of
patients with active cysts in the brain parenchyma. A recent
randomized controlled trial enrolling patients with at least one
active cyst and a history of seizures found that the combina-
tion of albendazole and praziquantel was significantly more
Table 3. Currently available antiparasitic drug regimens for parasitic infections
of the CNS.
Neurocysticercosis ● Albendazole with corticosteroids
● Praziquantel (alternative to albendazole) with
corticosteroids
● Combined albendazole/praziquantel with corticoster-
oids if >2 active parenchymal cysts
Toxoplasmosis ● Sulfadiazine + pyrimethamine with leucovorin
● Clindamycin (or atovaquone) + pyrimethamine with
leucovorin (alternative)
● Trimethoprim-sulfamethoxazole (alternative)
Echinococcosis ● Albendazole or mebendazole (alone or with surgery)
Schistosomiasis ● Praziquantel (after starting corticosteroid treatment)
Paragonimiasis ● Praziquantel
● Triclabendazole
Cerebral malaria Severe falciparum malaria
● IV artesunate
● IV quinine dihydrochloride or quinidine gluconate
∘ + doxycycline, tetracycline, or clindamycin
Toxocariasis ● Albendazole with corticosteroids
● Mebendazole (alternative to albendazole) with
corticosteroids
Onchocerciasis ● Ivermectin
● Doxycycline
American
trypanosomiasis
Acute or chronic infection
● Benznidazole
● Nifurtimox
African
trypanosomiasis
Early infection
● Trypanosoma brucei gambiense
∘ Pentamidine
∘ Suramin (alternative)
● Trypanosoma brucei rhodesiense
∘ Suramin
Late infection
● Trypanosoma brucei gambiense
∘ Eflornithine + nifurtimox
∘ Eflornithine monotherapy
∘ Melarsoprol (alternative) with corticosteroids
● Trypanosoma brucei rhodesiense
● Melarsoprol
Angiostrongyliasis ● None (corticosteroids and symptomatic treatment
only)
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effective than albendazole monotherapy in resulting in com-
plete cyst disappearance in patients with three or more active
cysts [56], and not significantly more effective in patients with
one or two cysts, confirming results of a previous study in
children [57]. Although this treatment was more effective in
eradicating the parasite in patients with multiple active cysts,
it was not associated with a greater proportion of patients
with complete seizure remission. Despite this progress for
parenchymal NCC, there is little evidence for treating extra-
parenchymal disease. As this form of the disease has a much
worse prognosis and is associated with higher fatality, many
questions remain about which antihelminthic agent (or poten-
tially combination of agents), dose, and treatment duration is
necessary.
There are no specific trials providing evidence for mana-
ging or treating CNS involvement in acute or chronic CD. In
general, the role of antiparasitic treatment has been unclear in
the chronic stage of disease, but a recent large randomized
controlled trial of a course of benznidazole versus placebo in
patients with chronic CD cardiomyopathy has provided impor-
tant evidence that may be relevant for patients with different
manifestations of the disease [58]. This trial found that benz-
nidazole treatment was associated with a significant reduction
in parasitemia, but unfortunately, there were no significant
effects of the drug seen in clinical efficacy end points.
However, a reassuring aspect of this study is that the safety
and tolerability of benznidazole were much better than
observed in previous observational studies.
The arsenal for treatment of the second, meningoencepha-
litic stage of Trypanosoma brucei gambiense HAT has been
long characterized by highly toxic compounds such as melar-
soprol, which is associated with a substantial rate of reactive
meningoencephalopathy and on-treatment death. A mile-
stone for the treatment of second-stage Trypanosoma brucei
gambiense HAT has been nifurtimox–eflornithine combination
therapy (NECT), which consists of IV nifurtimox for 10 days and
intravenous eflornithine for 7 days, and is now on the World
Health Organization (WHO) Essential Medicines List. A recent
retrospective cohort study of patients treated at Médicins Sans
Frontièrs-supported hospitals in northeastern Democratic
Republic of the Congo provided information about NECT in
the ‘real world’ setting outside of clinical trials [59]. This study
provided strong confirmatory evidence of the efficacy and
safety observed in clinical trials, with high cure rates, very
low rates of in-hospital mortality and low rates of major
adverse events. Of particular note, children appeared to toler-
ate NECT particularly well compared with adults, who had
about four times greater odds of experiencing an adverse
event.
For Trypanosoma brucei rhodesiense, NECT is unlikely to be
effective against second-stage HAT, leaving melarsoprol as the
only effect treatment option. Despite the safety concerns with
this agent, some progress has been made to improve its use in
clinical practice. Treatment for second stage Trypanosoma
brucei rhodesiense HAT is country protocol-specific and has
typically included suramin pre-treatment, followed by melar-
soprol infusions, which are separated by 5–7 day resting per-
iods, with an overall hospitalization of approximately 1 month.
A dual-publication of a proof-of-concept trial and utilization
study explored a 10-day melarsoprol regimen for Trypanosoma
brucei rhodesiense [60]. In this study, the 10-day melarsoprol
regimen had a similar incidence of encephalopathic syndrome
and case fatality relative to historic data. Parasitic and clinical
cure rates were high, with mean hospitalization time reduced
from 29 to 13 days. Furthermore, there was no observed
benefit of suramin pre-treatment, which has not been an
evidence-based practice. This regimen should now be consid-
ered the preferred regimen for treating second-stage
Trypanosoma brucei rhodesiense HAT.
Ivermectin has been the gold-standard treatment for onch-
ocerciasis, but there is concern about the reliance on one
solitary drug, and uncertainty about how to handle apparent
treatment failures and situations where ivermectin cannot be
used. A recent randomized controlled trial conducted in
Ghana provided formal data on the efficacy and safety of
doxycycline [61]. This trial compared a 6-week course of daily
doxycycline versus placebo among patients recruited in areas
with suboptimal response to ivermectin (i.e. significant micro-
filaridermia despite a history of multiple rounds of ivermectin
treatment). At 20 months’ follow-up, doxycycline treatment
was associated with a much lower proportion of Wolbachia
positive living female worms, much greater freedom from
microfilaridermia, and greater number of dead worms com-
pared with placebo. These data on doxycycline treatment are
particularly relevant when treating patients co-infected with
Loa loa, who are at increased risk for life-threatening ence-
phalopathy when given ivermectin.
Aside from antiparasitic treatment, adjunctive treatment is
a cornerstone of managing parasitic infections of the CNS,
particularly in cerebral malaria, where patients are managed
in intensive care units and mortality is high. Two issues related
to adjunctive care in cerebral malaria are managing cerebral
edema and starting enteral feeding.
Mild to moderate edema is a common finding on CT in
patients with cerebral malaria, but its role in the pathophysiol-
ogy of cerebral malaria has been unclear. Nevertheless, osmo-
tic diuretics, such a mannitol, have often been routinely used
to treat this cerebral edema. A randomized controlled trial
conducted in India sought to determine if this treatment was
in fact beneficial [62]. In this open-label trial, adult patients
with cerebral malaria and cerebral edema were randomized to
receive either no treatment or a regimen of mannitol infu-
sions. Not only was degree of cerebral edema not associated
with coma depth or mortality, but patients who received
mannitol had significantly longer coma recovery time and
nonsignificantly higher mortality.
In general, enteral feeding is often started soon after admis-
sion and intubation in the intensive care unit as it can improve
outcomes; however, endotracheal intubation is not always rea-
listic, particularly in resource-poor settings. To explore the clinical
utility and safety of early enteral feeding in non-intubated
patients with cerebral malaria, a trial in Bangladesh randomized
patients to receive enteral feeding through nasogastric tube
either early (upon admission) or late (up to 60 h in adults or
36 h in children) after hospitalization [63]. The trial was stopped
early because ofmuch higher incidence of aspiration pneumonia
in the early feeding group relative to the late feeding group.
Aside from the applicability of these results to practice, this trial
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highlights the importance considering the practicalities of
resource-poor settings when using an evidence-based approach
to manage and treat parasitic infections of the CNS.
Burden, control and elimination of parasitic diseases
of the CNS
There are approximately one billion people who are affected
by one or more neglected tropical disease (NTD). These dis-
eases are considered ‘neglected’ because they occur mostly in
the poorest of populations [19]. Among these NTDs are several
parasitic infections that affect the CNS. Table 4 details the
approximate prevalence and burden of some parasitic dis-
eases that can affect the CNS [64–69].
While disability-adjusted life years (DALYs) are a good
objective measure of the burden of disease, because of meth-
odological challenges, these figures generally underestimate
the disability associated with parasitic infections. In addition,
they do not take into account the economic or social losses
because of impact on productivity or stigma [68].
Parasitic infections of CNS are largely preventable and
highly burdensome. For example, NCC is known to cause
epilepsy and other neurological sequelae, and is the most
frequent preventable cause of epilepsy in developing coun-
tries [70]. A recent meta-analysis revealed that brain lesions
attributed to NCC are present in approximately 29.0% (95%
CI: 22.9–35.5%) of people with epilepsy in populations living
in Taenia solium endemic areas in settings with poor sanita-
tion and pig management practices and where pork is con-
sumed [71]. In these areas, the burden of epilepsy is almost
6.8 million DALYs per year [72] and mortality because of
NCC is about 3–6 times higher than in the general popula-
tion [70]. However, these rates are likely underestimations,
because of inadequate diagnosis and incomplete reporting
in low resource settings and because other important asso-
ciated symptoms, such as chronic headache, hydrocephalus,
stroke, and depressive disorders have not yet been taken
into account when calculating burden estimations [10].
Figure 3 illustrates countries and areas at risk for cysticer-
cosis [73].
In the year 2015, approximately 3.2 billion people –
nearly half of the world’s population – were at risk for
malaria. Malaria accounts for 3.3% of all DALYs and is
ranked seventh among the top leading causes of DALYs
globally [69]. Sub-Saharan Africa continues to carry a dis-
proportionately high share of the global malaria burden,
being home to 89% of malaria cases and 91% of malaria
deaths. In 2015, an estimated 438,000 deaths were related
to malaria. Young children, pregnant women and non-
immune travelers from malaria-free areas are particularly
vulnerable to the disease when they become infected [66].
Although data on the economic burden of parasitic
diseases are confined to small studies in limited geogra-
phical areas, the costs for individuals, healthcare systems
and economies are grossly high. For example, the mone-
tary cost of cysticercosis is estimated at US$15.27 million in
India, US$28.3 million in Honduras and US$16.6 million in
the Eastern Cape province (South Africa). In Latin America,
Table 4. Approximate prevalence and disability-adjusted life years (DALYs) of
common parasitic infections.
Parasitic disease
Approximate
worldwide
prevalence
Estimated DALYs (in millions)
– From Global Burden of
Disease (GBD) 2010 (95% CI)
Cysticercosis 50 million 0.50 (0.38–0.66)
Echinococcosis (Hydatidosis) 1 million 0.14 (0.07–0.29)
Schistosomiasis 207 million 3.31 (1.70–6.26)
Malaria 214 million 82.7 (63.4–109.8)
Onchocerciasis 42 million 0.49 (0.36–0.66)
American trypanosomiasis 10 million 0.55 (0.27–1.05)
African trypanosomiasis 50,000 to
70,000
0.56 (0.08–1.77)
Figure 3. Countries and areas at risk for cysticercosis.
Reprinted from: World Health Organization. Assembling a Framework for Intensified Control of Taeniasis and Neurocysicercosis caused by Taenia solium, 2013.
Available at: http://apps.who.int/iris/bitstream/10665/153237/1/9789241508452_eng.pdf?ua=1 [Last accessed 29 December 2015].
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CD is estimated to account for 752,000 lost working days
per year because of premature deaths, at a cost of over US
$1.2 billion per year [74]. There is also an unquantifiable
dimension to the burden of parasitic diseases that reduces
the productivity of millions of women who care for families
and maintain households in countries where such diseases
are endemic. Additionally, in low- and middle-income
countries, children are an economic resource and by
improving their health, these economies would be much
better off.
Prevention and control
In the year 2011, WHO adopted a roadmap for the control and
elimination of NTDs, including many parasites that affect the
CNS [19]. Principles for action include:
(i) A focus on populations and interventions rather than
specific diseases;
(ii) The introduction of innovative tools for parasite detec-
tion and control;
(iii) A multi-disease, intersectorial and interprogrammatic
approach.
This framework endorses the combination of several strategic
approaches, including (i) community sensitization and mobili-
zation campaigns; (ii) chemoprevention; (iii) intensified case-
management; (iv) symptomatic management; (v) vector con-
trol; (vi) provision of safe food and water, sanitation and
hygiene; and (vii) veterinary public health to prevent animal
to human transmission. Furthermore, strategies should be
cost-effective, ethical, environmentally sustainable, and applic-
able within local health structures and agricultural sys-
tems [19].
Many large-scale programs for control, elimination or era-
dication are being implemented by WHO and other partners
and stakeholders. Multi-pronged interventions have already
benefited millions of people, including the expansion of
malaria interventions, which have helped to reduce malaria
incidence by 30% globally and by 34% in Africa. This inter-
disciplinary approach included vector control through insecti-
cide-treated mosquito nets and indoor residual spraying,
public awareness strategies, symptomatic treatment, as well
as seasonal malaria chemoprevention. Since 2000, the preva-
lence of malaria parasite infection (including both sympto-
matic and asymptomatic infections) has decreased
significantly in Africa, falling from 173 million to 128 million
in 2013 – a reduction of 26%. This has occurred despite a 43%
increase in the African population living in malaria transmis-
sion areas [75].
Similar work to control and eliminate other parasites has
been conducted, including a sustained national schistosomia-
sis control program in many countries, such as China, which
has interrupted transmission in most endemic areas through a
comprehensive multi-faceted strategy including the construc-
tion of dams, delivery of potable water and providing basic
sanitation [19]. In 2014 Ecuador became the second country in
the world after Colombia in 2013 to be declared free of
onchocerciasis after successfully implementing elimination
activities for decades, which included community-directed
treatment with ivermectin [76].
Many World Health Assembly (WHA) resolutions have
provided a mandate for countries, as well as other stake-
holders, to become more active in this area. These include
the adoption of an updated resolution on the NTDs in 2013
strengthening efforts to prevent, control, eliminate or era-
dicate NTDs. In addition, there are specific resolutions
addressing the policies and technical assistance required
by countries to deal with many parasitic diseases that affect
the CNS [77]. Likewise, many disease-specific resolutions
have also been adopted and have highlighted that further
investments are required regarding preventing parasitic-
related neurological diseases, including the epilepsy resolu-
tion endorsed in 2015, which includes reference to NCC and
its prevention [78].
While there are barriers, it is entirely possible to control or
eliminate or eradicate parasitic diseases. During the past
decade, there has been an improved recognition that
human-, animal- and ecosystem-health are inextricably
linked. The international community, as well as local commu-
nity partners, have committed to bringing resources and
expertise to the task of overcoming parasitic and other vec-
tor-borne diseases. This has included the concept of ‘One
Health,’ and the corresponding approach, which aims to
bring together human health care practitioners, veterinarians,
public health and environmental health professionals. This
collaboration reduces the gaps between institutions and dis-
ciplines that can cause costly delays, and even failures, in
disease detection and control [79]. The use of an intersectoral
approach in many settings indicates improved cost–effective-
ness and ensures treatment coverage reaches neglected
populations [70].
Overcoming parasite-related disease makes sense both for
economies and for development. Without a significant reduc-
tion in the burden of these diseases, the achievement of other
health-related goals as well as those in education, gender
equality, poverty reduction and economic growth will be jeo-
pardized. Improving the control and elimination of parasitic
disease is therefore key to achieving the Sustainable
Development Goals (SDGs). By tackling parasitic diseases,
more than one billion people living in low-income endemic
areas have a chance for improved health and wellbeing. These
diseases should be neglected no more.
Expert commentary
Parasitic diseases of the CNS that were previously labeled as
‘exotic’ diseases are a serious global health issue. Parasites specific
to humans might accidently be located in abnormal or ectopic
locations, including the brain or spinal cord. However, precise
estimates of prevalence and burden of many of these diseases
are lacking, and information on the pathogenesis of CNS lesions is
limited. Parasitic infections in the CNS can present with a wide
range of clinical manifestations, which range from fulminant to
insidious onset and chronic progressive to relapsing-remitting
courses. Most of these diseases have specific findings in relation
to areas of involvement of the CNS and can sometimes have
overlapping imaging features. Based on a high clinical index of
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suspicion, patient demographics, and specific laboratory investi-
gations, a proper diagnosis can be made. Diagnosis of parasitic
infections relies on the demonstration of an offending organism
using laboratory investigations. Nevertheless, neuroimaging stu-
dies play an important role in reliable and early diagnosis. In terms
of treatment, substantial progress has been made in developing
an evidence base for existing drugs and treatment approaches.
However, new therapeutic agents are needed for some infections,
particularly in light of the suboptimal efficacy and high toxicity of
some agents. Ultimately, prevention and control are needed to
progress towards eradicating these diseases.
Five-year view
The genome of some parasites, particularly Taenia solium, will
soon be sequenced, and this may improve our knowledge of
mechanisms of pathogenesis and the genetic role in disease
heterogeneity. CNS parasitic diseases, especially NCC, are
probably a risk factor for both acute seizures and acquired
epilepsy in endemic countries. An interesting theory to con-
sider NCC as a human model of epileptogenesis has been
proposed; however, prospective cohort studies are needed to
assess the association of different evolutionary phases of the
parasite, potential genetic predisposition, and the role of
precipitating factors in the development of seizures and
epilepsy. In this context, use of International League
Against Epilepsy guidelines for epidemiological studies to
standardized concepts of classification of epilepsy is
mandatory.
Many of current diagnostic strategies for detecting para-
sites are labor intensive, insensitive and in the case of serol-
ogy, not necessarily indicative of current active infection.
Clearly, additional research into the safety, practicality, and
feasibility of immunological and molecular diagnosis is war-
ranted. Molecular methods with high sensitivity and specifi-
city for the detection of parasites that provide prognostic
information to the clinician are an aspect of care that has
been absent in the field of parasitology. Management of
parasitic infections will necessarily be advanced by improved
diagnostic capabilities. Molecular methods are also likely to
play an increasingly important role in determination of drug
resistance.
Regarding prevention and control, despite the gains
obtained by the WHO programs, continuing challenges remain
for the future. These are predominantly related to:
● Quantification of burden among neglected populations;
● Urgent development, improvements and accessibility of
diagnostic tools;
● Provision of treatment and other interventions to com-
munities in need;
● Procurement and supply of medicines and a system for
delivery of these to cover at-risk populations;
● Innovation of more effective medicines, vaccines and
insecticides;
● Promotion of integrated vector management;
● Early protection of children and other special popula-
tions, including those with HIV;
● Surveillance and monitoring.
Future field interventions should meet basic methodological
requirements: (i) an adequate study design and use of
validated surveys in community-based studies; (ii) case–con-
trol studies with high levels of exposure to parasites, (iii)
sufficient statistical power by recruiting adequate numbers
of people with epilepsy and their control, (iv) matching of
controls by sex, age, location and confounders, and (v)
neuroimaging, molecular (PCR), and serological assays (Ag-
ELISA and EITB) and CSF should be performed for all
included participants.
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Key issues
● CNS parasitic infections can be life-threatening, but are often preventable and treatable; however, clinical outcomes largely depend on early diagnosis
and treatment.
● Host and parasite factors involved in clinical heterogeneity and brain inflammation are beginning to be deciphered and will provide new clues to better
management of these diseases in the future.
● Evidence-based recommendations for management of parasitic infections warrant much additional investment and research in the coming years.
● Anti-parasite antibodies are synthesized soon after host invasion and so their detection is still the most frequently employed diagnostic tool. However,
their detection is not definitive proof of a current, viable infection as antibodies can persist for months, even years, after elimination of the parasite.
● The development of specific and sensitive serodiagnostic and molecular biological (PCR) assays for viable parasites is an urgent priority that will
complement and confirm clinical examination.
● Neuroimaging studies (CT scan and MRI) play an important role in early diagnosis; however, there is a wide range of neuroimaging findings in CNS
parasite infections, often with considerable overlap, which makes diagnosis difficult.
● Many large-scale programs for control, elimination or eradication are being implemented by WHO and other partners and stakeholders.
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